Infrared Spectrometry Method Used for Triage of Brain Cancer Patients
By LabMedica International staff writers Posted on 23 Oct 2019 |
Image: An example of an FTIR spectrometer with an attenuated total reflectance (ATR) attachment (Photo courtesy of Wikimedia Commons).
A team of British researchers has adapted an advanced spectrophotometric method for use in brain cancer testing as a triage tool to speed up the diagnostic process.
Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this scenario.
Towards this end, investigators at the University of Strathclyde (Glasgow, United Kingdom), the spinoff biotechnology company ClinSpec Diagnostics Limited (Glasgow, United Kingdom), and colleagues at other institutions developed instrumentation based on testing blood samples by attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy to differentiate cancer and control patients.
Fourier-transform infrared spectroscopy (FTIR) is a technique used to obtain an infrared spectrum of absorption or emission of a solid, liquid, or gas. An FTIR spectrometer simultaneously collects high-spectral-resolution data over a wide spectral range. This confers a significant advantage over a dispersive spectrometer, which measures intensity over a narrow range of wavelengths at a time. The term Fourier-transform infrared spectroscopy originates from the fact that a Fourier transform (a mathematical process) is required to convert the raw data into the actual spectrum. Attenuated total reflection (ATR) is a sampling technique used in conjunction with infrared spectroscopy, which enables samples to be examined directly in the solid or liquid state without further preparation.
The investigators developed disposable sample slides that allowed the rapid preparation and analysis of multiple samples, enabling high-throughput ATR-FTIR spectroscopy optimized for clinical research. Based upon the design of a microscope slide, these optical sample slides contained four sample areas; one for background measurements and three for repeat measurements of a single patient. This device was developed for the triplicate measurement of patient samples with optimized spectral throughput and performance.
The investigators described the transition to this technology for the established application of ATR-FTIR spectroscopy of blood serum for the detection of brain cancer, and the subsequent impact on clinical diagnostics. In the current study, they analyzed samples from a prospective cohort of 104 patients and found that the blood test was able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%, respectively.
Senior author Dr. Matthew J. Baker, reader in pure and applied chemistry at Strathclyde University and CSO at ClinSpec Diagnostics, said, "This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumors in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services."
The clinical feasibility study was published in the October 8, 2019, online edition of the journal Nature Communications.
Related Links:
University of Strathclyde
ClinSpec Diagnostics Limited
Non-specific symptoms, as well as the lack of a cost-effective test to triage patients in primary care, has resulted in increased time-to-diagnosis and a poor prognosis for brain cancer patients. A rapid, cost-effective, triage test could significantly improve this scenario.
Towards this end, investigators at the University of Strathclyde (Glasgow, United Kingdom), the spinoff biotechnology company ClinSpec Diagnostics Limited (Glasgow, United Kingdom), and colleagues at other institutions developed instrumentation based on testing blood samples by attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy to differentiate cancer and control patients.
Fourier-transform infrared spectroscopy (FTIR) is a technique used to obtain an infrared spectrum of absorption or emission of a solid, liquid, or gas. An FTIR spectrometer simultaneously collects high-spectral-resolution data over a wide spectral range. This confers a significant advantage over a dispersive spectrometer, which measures intensity over a narrow range of wavelengths at a time. The term Fourier-transform infrared spectroscopy originates from the fact that a Fourier transform (a mathematical process) is required to convert the raw data into the actual spectrum. Attenuated total reflection (ATR) is a sampling technique used in conjunction with infrared spectroscopy, which enables samples to be examined directly in the solid or liquid state without further preparation.
The investigators developed disposable sample slides that allowed the rapid preparation and analysis of multiple samples, enabling high-throughput ATR-FTIR spectroscopy optimized for clinical research. Based upon the design of a microscope slide, these optical sample slides contained four sample areas; one for background measurements and three for repeat measurements of a single patient. This device was developed for the triplicate measurement of patient samples with optimized spectral throughput and performance.
The investigators described the transition to this technology for the established application of ATR-FTIR spectroscopy of blood serum for the detection of brain cancer, and the subsequent impact on clinical diagnostics. In the current study, they analyzed samples from a prospective cohort of 104 patients and found that the blood test was able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%, respectively.
Senior author Dr. Matthew J. Baker, reader in pure and applied chemistry at Strathclyde University and CSO at ClinSpec Diagnostics, said, "This is the first publication of data from our clinical feasibility study and it is the first demonstration that our blood test works in the clinic. Earlier detection of brain tumors in the diagnostic pathway brings the potential to significantly improve patient quality of life and survival, whilst also providing savings to the health services."
The clinical feasibility study was published in the October 8, 2019, online edition of the journal Nature Communications.
Related Links:
University of Strathclyde
ClinSpec Diagnostics Limited
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans